Search research articles
Contact Us
Filters
Showing results (161-170 of 178) with videos related to
Page
of 18
Sort By:
Melanoma Research
|
December 22, 1999
Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma)
M R Sertoli, P Queirolo, E Bajetta, et al.
British Journal of Cancer
|
January 25, 2007
Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study
E Bajetta, M Di Bartolomeo, R Buzzoni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 18, 2011
Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings
J Beck, G Procopio, E Bajetta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 2, 2008
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
F Perrone, A Lampis, M Orsenigo, et al.
British Journal of Cancer
|
November 28, 2007
Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab
S Siena, M Peeters, E Van Cutsem, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 6, 2007
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy
E Van Cutsem, S Siena, Y Humblet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 1, 1997
A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. The Italian Trials in Medical Oncology (I.T.M.O.) group
E Bajetta, N Zilembo, S Barni, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 15, 2005
Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy
S I Helle, W Mietlowski, J P Guastalla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2000
Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial
P E Lønning, E Bajetta, R Murray, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 12, 2002
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin
J Cassidy, C Twelves, E Van Cutsem, et al.
Page
of 18
Search research articles
Search
Showing results (161-170 of 178) with videos related to
Sort By:
Page
of 18
Melanoma Research
|
December 22, 1999
Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma)
M R Sertoli, P Queirolo, E Bajetta, et al.
British Journal of Cancer
|
January 25, 2007
Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study
E Bajetta, M Di Bartolomeo, R Buzzoni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 18, 2011
Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings
J Beck, G Procopio, E Bajetta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 2, 2008
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients
F Perrone, A Lampis, M Orsenigo, et al.
British Journal of Cancer
|
November 28, 2007
Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab
S Siena, M Peeters, E Van Cutsem, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 6, 2007
An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy
E Van Cutsem, S Siena, Y Humblet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 1, 1997
A multicentre, randomized, pharmacokinetic, endocrine and clinical study to evaluate formestane in breast cancer patients at first relapse: endocrine and clinical results. The Italian Trials in Medical Oncology (I.T.M.O.) group
E Bajetta, N Zilembo, S Barni, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 15, 2005
Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy
S I Helle, W Mietlowski, J P Guastalla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2000
Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial
P E Lønning, E Bajetta, R Murray, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 12, 2002
First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin
J Cassidy, C Twelves, E Van Cutsem, et al.
Page
of 18